Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
CommuniquÚs de presse de la sociÚtÚ BRISTOL-MYERS SQUIBB COMPANY
09/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Ap..
BU
09/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
BU
09/17BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
BU
09/16BRISTOL MYERS SQUIBB : Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yer..
BU
09/13BRISTOL MYERS SQUIBB : According to New Multinational Survey, Healthcare Providers Believe..
BU
09/13BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Ov..
BU
09/10BRISTOL MYERS SQUIBB : Shares Research Supporting Correlation Between New York Heart Assoc..
BU
09/09BRISTOL MYERS SQUIBB : Announces Dividend
BU
09/08BRISTOL MYERS SQUIBB : Bolt Biotherapeutics Announces Clinical Collaboration with Bristol ..
AQ
09/08BRISTOL MYERS SQUIBB : to Report Results for Third Quarter 2021 on October 27, 2021
BU
09/08BRISTOL MYERS SQUIBB : More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. ..
BU
09/08BRISTOL MYERS SQUIBB : Research at ESMO 2021 Demonstrates Clinical Benefits of Immunothera..
BU
09/07UPDATED STATEMENT : Bristol Myers Squibb on Coronavirus (COVID-19)
PU
09/07BRISTOL MYERS SQUIBB : to Take Part in Morgan Stanley 19th Annual Global Healthcare Confer..
BU
09/03BRISTOL MYERS SQUIBB : Pfizer Alliance is pleased with the decision by the U.S. Court of A..
PU
08/27BRISTOL MYERS SQUIBB : Sixth Circuit Limits Exercise Of Personal Jurisdiction In FLSA Coll..
AQ
08/23BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
BU
08/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo« (nivolumab) for ..
BU
08/19BRISTOL MYERS SQUIBB : Receives European Commission Approval for Abecma (Idecabtagene Vicl..
BU
08/17BRISTOL MYERS SQUIBB : EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivol..
BU
08/16THIS WEEK AT THE NINTH : Class Objections And Robocalls
AQ
08/10BRISTOL MYERS SQUIBB : and Five Leading Historically Black Colleges and Universities Launc..
BU
08/09BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements ..
AQ
08/03BRISTOL MYERS SQUIBB : Completes Sale of Manufacturing Facility in Couvet, Switzerland
BU
08/03BRISTOL MYERS SQUIBB : Statement on Istodax« (romidepsin) Relapsed/Refractory Peripheral T..
PU
07/30BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolumab) as Adj..
BU
07/28BRISTOL MYERS SQUIBB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
07/28BRIDGEBIO PHARMA : Announces Clinical Collaboration With Bristol Myers Squibb To Study BBP..
AQ
07/28BRISTOL MYERS SQUIBB : Quarterly Package of Financial Information (XLS) Excel 2.28 MB
PU
07/28BRISTOL MYERS SQUIBB : Q2 2021 Presentation
PU
07/28BRISTOL MYERS SQUIBB : Reports Second Quarter Financial Results for 2021 (Form 8-K)
PU
07/28BRISTOL MYERS SQUIBB CO : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
07/28BRISTOL MYERS : Q2 Earnings Snapshot
AQ
07/28BRISTOL MYERS SQUIBB : Reports Second Quarter Financial Results for 2021
BU
07/23BRISTOL MYERS SQUIBB : Statement on Opdivo« (nivolumab) Monotherapy Post-Sorafenib Hepatoc..
PU
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/19BRISTOL MYERS SQUIBB : MPN Hub continues to enhance global knowledge of myeloproliferative..
AQ
07/19AML Hub continues to enhance global knowledge of acute myeloid leukemia throughout 2021
AQ
07/16BRISTOL MYERS SQUIBB : Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivoluma..
BU
06/29BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolumab) Plus Y..
BU
06/25BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant T..
BU
06/25BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abe..
BU
06/18BRISTOL MYERS SQUIBB : Receives European Commission Approval for Onureg« (azacitidine tabl..
BU
06/17BRISTOL MYERS SQUIBB : Eisai and Bristol Myers Squibb Enter Into Global Strategic Collabor..
BU
06/17BRISTOL MYERS SQUIBB : Announces Dividend
BU
06/11BRISTOL MYERS SQUIBB : and Acceleron Present First Results from Phase 2 BEYOND Study of Re..
BU
06/10BRISTOL MYERS SQUIBB : and GRYT Health Evolve Virtual Patient Advocacy Experience
BU
06/10BRISTOL MYERS SQUIBB : to Report Results for Second Quarter 2021 on July 28, 2021
BU
06/10BRISTOL MYERS SQUIBB : Announces Positive Topline Results from Phase 3 TRANSFORM Trial Eva..
BU
06/07EXELIXIS : Announces Positive Phase 2 Results for CABOMETYX (cabozantinib) in Combination ..
AQ
06/07Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase ..
AQ
06/04BRISTOL MYERS SQUIBB : to Take Part in Goldman Sachs 42nd Annual Global Healthcare Confere..
BU
06/03BRISTOL MYERS SQUIBB : Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy ..
BU
06/03BRISTOL MYERS SQUIBB : Dual Immunotherapy Regimen Delays Cancer Progression in Patients wi..
AQ
06/02BRISTOL MYERS SQUIBB : Health Canada Approves OPDIVO« (nivolumab) plus YERVOY« (ipilimumab..
AQ
06/02BRISTOL MYERS SQUIBB : Receives European Commission Approval for Opdivo (nivolumab) Plus Y..
BU
06/02BRISTOL MYERS SQUIBB : Data at EULAR 2021 Highlight Commitment to Driving Advancements Acr..
BU
05/28OSE IMMUNOTHERAPEUTICS : and the FoRT Foundation Announce Initiation of a Phase 2 Clinical..
AQ
05/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Bristol Myers Squibb's Z..
BU
05/26BRISTOL MYERS SQUIBB : to Take Part in Bernstein's 37th Annual Strategic Decisions Confere..
BU
05/25BRISTOL MYERS SQUIBB : Foundation Announces First Global Cancer Disparities Grants in Braz..
PU
05/25BRISTOL MYERS SQUIBB : Xencor and Bristol Myers Squibb Enter License Agreement for Use of ..
BU
05/25BRISTOL MYERS SQUIBB : to Host Virtual Investor Event to Discuss ASCO 2021 Highlights
BU
05/23BRISTOL MYERS SQUIBB : Presents New Data at Digestive Disease Week« on Zeposia (ozanimod) ..
BU
05/21BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus..
BU
05/20BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers, Financial Statements ..
AQ
05/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo« (nivolumab) as A..
BU
05/20BRISTOL MYERS SQUIBB : Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
BU
05/19BRISTOL MYERS SQUIBB : Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination ..
BU
05/19BRISTOL MYERS SQUIBB : Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate De..
BU
05/19BRISTOL MYERS SQUIBB : Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Do..
BU
05/19BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chem..
BU
05/19BRISTOL MYERS SQUIBB : Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long..
BU
05/18BRISTOL MYERS SQUIBB : Agenus and Bristol Myers Squibb Announce Exclusive Global License f..
AQ
05/18BRISTOL MYERS SQUIBB : to Take Part in UBS Global Healthcare Virtual Conference
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BRISTOL-MYERS SQUIBB COMPANY